CDTNasdaq

CDT Equity Inc.

Pharmaceutical Preparations · DE · CIK 1896212

CDT Equity Inc. develops therapeutic assets using AI, solid-form chemistry, and partnerships to accelerate novel treatments

red 8-K · 90d

+ Watch View on EDGAR ↗

$2M

Market cap

$0.38

Last close

-7.0%

-22.9%

213K

Volume

Price$0.38-99.9%· 1Y

Volume

Jul 10L $0.38 · H $482.00Jul 10

Revenue & earnings

RevenueNet incomeLoss

Fundamentals & quality

Fundamentals not yet available for this company.

Similar companies

Comparable business profile · signals at a glance

EQEquillium, Inc.$184.0M-1.7%CLDXCelldex Therapeutics, Inc.$3.0B+0.3%EDSAEdesa Biotech, Inc.$72.2M-0.1%CUECue Biopharma, Inc.$118.7M+0.7%CTNMContineum Therapeutics, Inc.

Filings archive

Newest first · each with a one-line AI read · showing 10 of 133

Jul 7, 20268-KMaterial Agreement · New Debt / ObligationCDT Equity Inc. amended its loan agreement and convertible promissory note to close the second tranche of a loan, which changed the payment schedule for the loan.Jun 29, 20268-KAuditor ChangeCDT Equity Inc. dismissed CBIZ CPAs P.C. as its independent registered public accounting firm and engaged Carr, Riggs & Ingram, L.L.C. as its new auditor, effective June 23, 2026. This change is related to material weaknesses in internal control over financial reporting.Jun 23, 2026SC 13D/ASC 13D/A

Material Agreement · New Debt / ObligationCDT Equity Inc. entered into a loan agreement for a senior secured convertible promissory note and issued warrants to J.J. Astor & Co. The company also announced this transaction via press release.